Biotechnology-Based Molecules in Oncology: 2021 IPO Review Pt. IV

This short article and poster summary takes a deeper look into the 2021 IPOs for biotechnology-based therapeutics being developed by oncology-focused companies, including:

  • Antibody-drug conjugates
  • Monoclonal antibodies
  • Protein-based therapeutics
  • Cell and gene therapies
  • Other biotechnology-based therapeutics

This article is Part 4 of a review series covering all of the initial public offerings for the biotech and pharmaceutical industries in 2021. Part 1 and Part 2 provided an overview of 2021 IPOs by therapy area, technology, and therapeutic class. Part 3 provided a deep dive into the 2021 IPOs for oncology-focused companies developing conventional small molecule therapeutics. 

request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.

already a member? log in:

Join the Drug Hunter mailing list

to get free content and resources weekly. Trusted by > 5,500 drug hunters worldwide. Unsubscribe anytime.

This field is for validation purposes and should be left unchanged.

Join Subscribers from

…and hundreds more!